The performance of Shangyao keeps rising. Today's China Daily has disclosed nearly 60 billion yuan

Recently, Shanghai Pharmaceutical Group released the first half of 2016 interim report, which disclosed that the operating revenue in the first half of 2016 was 59.695 billion yuan, an increase of 17.16% year on year The net profit attributable to shareholders of the listed company was 1.732 billion yuan, up 12.94% year on year Table 1 Details of Shanghai Pharmaceutical accounting data: the sales volume of Shanghai pharmaceutical industry has reached 6.41 billion for half a year From the data trend in the figure, it can be seen that in the past six years, the turnover of Shanghai pharmaceutical industry has been on the rise, with the largest increase in this year's turnover of 8.745 billion yuan From the above table, we can see that in the first half of 2016, the sales of Shanghai Pharmaceutical increased both at home and abroad, among which there was a significant increase in China, up to 17.31% In the past half year, the sales revenue of Shanghai pharmaceutical industry was 6.41 billion yuan, up 5.34% year on year Among them, the sales revenue of Shangyao chemical and biochemical medicine sector reached 2.983 billion yuan, a year-on-year increase of 5.52%; the sales revenue of traditional Chinese medicine sector (proprietary Chinese medicine, herbal pieces) reached 2.233 billion yuan, a year-on-year increase of 8.36%; the sales revenue of biological medicine sector was 207 million yuan, a year-on-year increase of 4.07%; the sales revenue of other industrial products (APIs, health products, medical devices, etc.) reached 988 million yuan, Down 1.15% year on year Over the past year, Shangyao has continued to implement the focus strategy for key products, with sales revenue of 60 key varieties reaching 3.48 billion yuan, up 9.26% year on year 39 of the key products are higher than or equal to the growth of IMS's similar products It is estimated that the annual sales revenue of the 24 varieties that Shanghai Pharmaceutical focuses on can exceed 100 million yuan The specific situation is as follows: the continuous R & D innovation is only in June, and the number of clinical approvals has reached 22 In the past, Shanghai Pharmaceutical still maintains a high R & D investment, with a total investment of 288 million yuan in the first half of the year, accounting for 4.5% of the industrial sales revenue The research and development projects are mainly five items, including dotipofen, sph3127, sph1188, Fc fusion protein of TNFa receptor, and recombinant anti-CD20 humanized monoclonal antibody injection 58 new invention patents have been applied for and 26 invention patents have been authorized As of the end of the reporting period, there are 286 invention patents in total In addition, the sales revenue of R & D listed new products in half a year is 856 million yuan, accounting for 13.35% of the company's industrial sales revenue During the reporting period, there were 22 clinical approvals (see Table 4 for details) and 3 clinical approvals (see Table 5 for details) of the approved drugs Shangyao also signed a contract with Sichuan University for the research and development of pulmonary fibrosis drugs, and launched a comprehensive cooperation with Sichuan University In the first half of this year, Shanghai Pharmaceutical Group's "R & D and industrialization of recombinant human type 5 adenovirus injection (ankeri) for treatment of malignant tumors" project won the second prize of Shanghai Science and technology award issued by Shanghai Municipal People's government; "analysis of ginkgolide composition" project was jointly awarded by the federal government of Switzerland, the state government of Geneva, the municipal government of Geneva and the World Intellectual Property Organization Geneva International Invention Exhibition gold medal Compared with figure 1 and Figure 2, it is not difficult to see that in order to obtain higher profits, we must increase the investment in innovative drugs, actively respond to the guidelines of the country's transformation from a big manufacturing country to an innovative one, and transform China's manufacturing into China's creation.